Anti-oxidative or anti-inflammatory additives reduce ischemia/reperfusions injury in an animal model of cardiopulmonary bypass.
ACT, activated clotting time
AEC, 3-amino-9-ethylcarbazole
AIF, apoptosis-inducing factor
CO, cardiac output
CPB, cardio-pulmonary bypass
Cardio-pulmonary bypass
DNA, deoxyribonucleic acid
EF, ejection fraction
EGCG, epigallo-3-catechin-gallate
EGCG, ischemia/reperfusion injury
HIF1α, hypoxia-inducible factor α
HPLC, high pressure liquid chromatography
Heart
MPTP, mitochondrial permeability transition pore
Minocycline
NT, nitrotyrosine
PAR, poly-ADP-ribose
PARP, poly-ADP-ribose polymerase
ROS, reactive oxygen species
TNFα, tumor necrosis factor α
cC3, cleaved caspase-3
Journal
Saudi journal of biological sciences
ISSN: 1319-562X
Titre abrégé: Saudi J Biol Sci
Pays: Saudi Arabia
ID NLM: 101543796
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
05
11
2018
revised:
01
04
2019
accepted:
03
04
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
ppublish
Résumé
Severe inborn cardiac malformations are typically corrected in cardioplegia, with a cardio-pulmonary bypass (CPB) taking over body circulation. During the operation the arrested hearts are subjected to a global ischemia/reperfusion injury. Although the applied cardioplegic solutions have a certain protective effect, application of additional substances to reduce cardiac damage are of interest.18 domestic piglets (10-15 kg) were subjected to a 90 min CPB and a 120 min reperfusion phase without or with the application of epigallocatechin-3-gallate (10 mg/kg body weight) or minocycline (4 mg/kg body weight), with both drugs given before and after CPB. 18 additional sham-operated piglets without or with epigallocatechin-3-gallate or minocycline served as controls. In total 36 piglets were analyzed (3 CPB-groups and 3 control groups without or with epigallocatechin-3-gallate or minocycline respectively; 6 piglets per group). Hemodynamic and blood parameters and ATP-measurements were assessed. Moreover, a histological evaluation of the heart muscle was performed. Piglets of the CPB-group needed more catecholamine support to achieve sufficient blood pressure. Ejection fraction and cardiac output were not different between the 6 groups. However, cardiac ATP-levels and blood lactate were significantly lower and creatine kinase was significantly higher in the three CPB-groups. Markers of apoptosis, hypoxia, nitrosative and oxidative stress were significantly elevated in hearts of the CPB-group. Nevertheless, addition of epigallocatechin-3-gallate or minocycline significantly reduced markers of myocardial damage. Noteworthy, EGCG was more effective in reducing markers of hypoxia, whereas minocycline more efficiently decreased inflammation. While epigallocatechin-3-gallate or minocycline did not improve cardiac hemodynamics, markers of myocardial damage were significantly lower in the CPB-groups with epigallocatechin-3-gallate or minocycline supplementation.
Identifiants
pubmed: 31889812
doi: 10.1016/j.sjbs.2019.04.003
pii: S1319-562X(19)30047-6
pmc: PMC6933174
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18-29Informations de copyright
© 2019 King Saud University.
Références
Thorac Cardiovasc Surg. 1980 Oct;28(5):295-302
pubmed: 6161427
Biochem Pharmacol. 2009 Mar 1;77(5):888-96
pubmed: 19041852
Cornea. 2016 Feb;35(2):249-56
pubmed: 26583279
Korean J Physiol Pharmacol. 2011 Oct;15(5):259-66
pubmed: 22128257
J Neurosci. 2003 Sep 3;23(22):7967-73
pubmed: 12954857
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9685-90
pubmed: 16769901
Brain Res Bull. 2017 May;131:207-213
pubmed: 28454931
Artif Organs. 2014 Jan;38(1):11-8
pubmed: 24392866
Bioorg Med Chem Lett. 2017 Apr 15;27(8):1731-1736
pubmed: 28285917
Naunyn Schmiedebergs Arch Pharmacol. 2015 Jun;388(6):663-76
pubmed: 25772063
Eur J Pharmacol. 2011 Jul 1;661(1-3):15-21
pubmed: 21536024
J Cardiothorac Vasc Anesth. 1993 Aug;7(4 Suppl 2):19-25
pubmed: 8369465
J Cent Nerv Syst Dis. 2017 Jul 28;9:1179573517722512
pubmed: 28811745
Arch Pharm Res. 2014 Aug;37(8):1079-85
pubmed: 24307060
Cell Biochem Funct. 2013 Aug;31(6):451-9
pubmed: 23760768
Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1258-65
pubmed: 26331570
Aging Cell. 2013 Dec;12(6):1041-9
pubmed: 23834676
Eur Surg Res. 2011;46(1):19-25
pubmed: 21150207
Biomed Pharmacother. 2017 Oct;94:362-373
pubmed: 28772214
Eur J Clin Invest. 2000 Nov;30(11):938-46
pubmed: 11114955
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18314-9
pubmed: 17116881
Life Sci. 2017 Jun 1;178:61-69
pubmed: 28438640
Circulation. 2012 May 29;125(21):2578-87
pubmed: 22523313
Ann Thorac Surg. 2015 Jan;99(1):192-9
pubmed: 25440278
Cardiovasc Res. 2014 Oct 1;104(1):24-36
pubmed: 25063991
Ann Thorac Surg. 2016 Apr;101(4):1507-13
pubmed: 26675556
Toxicol Mech Methods. 2014 May;24(4):259-67
pubmed: 24392852
J Thorac Cardiovasc Surg. 1977 Dec;74(6):900-6
pubmed: 926815
Antimicrob Agents Chemother. 2009 May;53(5):1760-5
pubmed: 19258275
Cell Death Differ. 2001 Apr;8(4):367-76
pubmed: 11550088
Resuscitation. 2014 Feb;85(2):284-91
pubmed: 24513126
Ann Thorac Surg. 1995 Feb;59(2):398-402
pubmed: 7847955
Redox Biol. 2014 Jan 10;2:187-95
pubmed: 24494192
Orphanet J Rare Dis. 2009 Jan 13;4:2
pubmed: 19144126
Minn Med. 1954 Mar;37(3):171-85; passim
pubmed: 13154149
Cell Mol Life Sci. 2008 Apr;65(7-8):1133-49
pubmed: 18202826
Physiol Rev. 2007 Jan;87(1):315-424
pubmed: 17237348
Korean J Anesthesiol. 2012 Oct;63(4):340-5
pubmed: 23115687
Brain Pathol. 2015 Nov;25(6):733-42
pubmed: 25582287
Int J Mol Sci. 2018 Feb 23;19(2):null
pubmed: 29473846
J Physiol Pharmacol. 2017 Feb;68(1):99-116
pubmed: 28456774
Orphanet J Rare Dis. 2008 Oct 13;3:27
pubmed: 18851735
J Cardiothorac Vasc Anesth. 1998 Apr;12(2 Suppl 1):21-5
pubmed: 9583572
J Surg Res. 2016 Apr;201(2):313-25
pubmed: 27020813
PLoS One. 2015 Dec 14;10(12):e0143315
pubmed: 26655803
Neurosci Lett. 2006 May 8;398(3):195-200
pubmed: 16469440